The UK and US have signed a important trade agreement that will preserve zero import taxes on UK drug products being sold in the US market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to boost expenditure on pharmaceuticals through the NHS. This commitment secures that import taxes on these key products will stay at zero for a period of the next three years.
This agreement comes after earlier statements to dramatically increase tariffs on branded drug imports, with increases floated as high as 100%.
"This agreement between the UK strengthens the international landscape for cutting-edge drugs and brings long-overdue fairness to American-British medicine commerce," a statement said.
Economic Importance
Pharmaceuticals constitute one of the UK's largest goods shipped to the US, which is by far the biggest destination for leading British pharmaceutical firms.
Trade data indicate that in the 12 months prior to the third quarter, the UK shipped medicines totaling £11.1bn to the US. This value made up nearly one-fifth of all goods exports in that timeframe.
"This deal secures employment, boosts capital expenditure and paves the way for the UK to establish itself as a international leader for life sciences," a government official commented.
Key British Pledges
The agreement involves several notable pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new medicines to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to increase total NHS spending on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must pay back to the NHS to stay within budget will be restricted at fifteen percent. In the past, refunds exceeded twenty percent.
Broader Context
The pact takes place against a ongoing tension between the drug companies and the ministers over drug pricing and NHS adoption.
These tensions were intensified by assertions that American consumers were charged significantly more for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several major manufacturing plans in the UK have been paused or abandoned, while major investments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS had to spend more on drugs, noting that its expenditure on drugs had decreased as a percentage of its total funding over the past decade.
